Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography? Hunter B. Moore, MD, PhD, Ernest E. Moore, MD, FACS, Michael P. Chapman, MD, Kirk C. Hansen, PhD, Mitchell J. Cohen, MD, FACS, Frederic M. Pieracci, MD, MPH, FACS, James Chandler, BA, Angela Sauaia, MD, PhD Journal of the American College of Surgeons Volume 229, Issue 1, Pages 92-101 (July 2019) DOI: 10.1016/j.jamcollsurg.2019.03.015 Copyright © 2019 Terms and Conditions
Figure 1 Change in clot strength based on the differential functional fibrinogen thrombelastography. DFI, depletion of fibrinolysis inhibitors Journal of the American College of Surgeons 2019 229, 92-101DOI: (10.1016/j.jamcollsurg.2019.03.015) Copyright © 2019 Terms and Conditions
Figure 2 Differences in survival times between patients with depletion of fibrinolysis inhibitors stratified by fibrinolysis phenotype and whether they (A) did not receive tranexamic acid (TXA) or (B) did receive TXA. Patients who did not receive TXA hyperfibrinolysis had the highest mortality, and in the cohort of patients who received TXA mortality was higher in the shutdown cohort. Contrasting phenotypes, only TXA (p = 0.043) was associated with increased mortality in the physiologic cohort. Journal of the American College of Surgeons 2019 229, 92-101DOI: (10.1016/j.jamcollsurg.2019.03.015) Copyright © 2019 Terms and Conditions